BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 30582282)

  • 1. Noteworthy effect of slight variation in aliphatic chain length of trisubstituted imidazole inhibitors against epidermal growth factor receptor L858R/T790M/C797S mutant in cancer therapy.
    Akher FB; Farrokhzadeh A; Soliman MES
    Chem Biol Drug Des; 2019 May; 93(5):798-810. PubMed ID: 30582282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping.
    Juchum M; Günther M; Döring E; Sievers-Engler A; Lämmerhofer M; Laufer S
    J Med Chem; 2017 Jun; 60(11):4636-4656. PubMed ID: 28482151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.
    Günther M; Lategahn J; Juchum M; Döring E; Keul M; Engel J; Tumbrink HL; Rauh D; Laufer S
    J Med Chem; 2017 Jul; 60(13):5613-5637. PubMed ID: 28603991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational Computational Design of Fourth-Generation EGFR Inhibitors to Combat Drug-Resistant Non-Small Cell Lung Cancer.
    Park H; Jung HY; Kim K; Kim M; Hong S
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33297461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Covalent vs. Non-Covalent Inhibition: Tackling Drug Resistance in EGFR - A Thorough Dynamic Perspective.
    Akher FB; Farrokhzadeh A; Soliman MES
    Chem Biodivers; 2019 Mar; 16(3):e1800518. PubMed ID: 30548188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational and Synthetic approach with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S triple mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC).
    Karnik KS; Sarkate AP; Tiwari SV; Azad R; Burra PVLS; Wakte PS
    Bioorg Chem; 2021 Feb; 107():104612. PubMed ID: 33476869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Mechanistic Study of a Potent and Selective Epidermal Growth Factor Receptor Inhibitor against the L858R/T790M Resistance Mutation.
    Akher FB; Farrokhzadeh A; Ravenscroft N; Kuttel MM
    Biochemistry; 2019 Oct; 58(41):4246-4259. PubMed ID: 31589411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
    Jia Y; Yun CH; Park E; Ercan D; Manuia M; Juarez J; Xu C; Rhee K; Chen T; Zhang H; Palakurthi S; Jang J; Lelais G; DiDonato M; Bursulaya B; Michellys PY; Epple R; Marsilje TH; McNeill M; Lu W; Harris J; Bender S; Wong KK; Jänne PA; Eck MJ
    Nature; 2016 Jun; 534(7605):129-32. PubMed ID: 27251290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic Study of Potent Fluorinated EGFR Kinase Inhibitors with a Quinazoline Scaffold against L858R/T790M/C797S Resistance Mutation: Unveiling the Fluorine Substituent Cooperativity Effect on the Inhibitory Activity.
    Akher FB; Farrokhzadeh A; Ravenscroft N; Kuttel MM
    J Phys Chem B; 2020 Jul; 124(28):5813-5824. PubMed ID: 32603111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer.
    Yi Y; Wang L; Zhao D; Huang S; Wang C; Liu Z; Sun H; Liu K; Ma X; Li Y
    Chem Biol Drug Des; 2018 Dec; 92(6):1988-1997. PubMed ID: 30030903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of EGF Receptor Inhibitors That Are Selective for the d746-750/T790M/C797S Mutant through Structure-Based de Novo Design.
    Park H; Jung HY; Mah S; Hong S
    Angew Chem Int Ed Engl; 2017 Jun; 56(26):7634-7638. PubMed ID: 28493467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors.
    Heppner DE; Günther M; Wittlinger F; Laufer SA; Eck MJ
    J Med Chem; 2020 Apr; 63(8):4293-4305. PubMed ID: 32243152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Docking, Pharmacokinetic and Molecular Simulation Analysis of Novel Mono-Carbonyl Curcumin Analogs as L858R/T790M/C797S Mutant EGFR Inhibitors.
    Bhandari SV; Kuthe PV; Patil SM; Nagras OG; Sarkate AP; Chaudhari SY; Surve SV
    Chem Biodivers; 2023 Nov; 20(11):e202301081. PubMed ID: 37793119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFR
    Shen J; Zhang T; Zhu SJ; Sun M; Tong L; Lai M; Zhang R; Xu W; Wu R; Ding J; Yun CH; Xie H; Lu X; Ding K
    J Med Chem; 2019 Aug; 62(15):7302-7308. PubMed ID: 31298540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How Different Substitution Positions of F, Cl Atoms in Benzene Ring of 5-Methylpyrimidine Pyridine Derivatives Affect the Inhibition Ability of EGFR
    E J; Liu Y; Guan S; Luo Z; Han F; Han W; Wang S; Zhang H
    Molecules; 2020 Feb; 25(4):. PubMed ID: 32085409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational studies of potent covalent inhibitors on wild type or T790M/L858R mutant epidermal growth factor receptor.
    Yang Z; Yang H; Ai Y; Zhang L; Li Z; Wan S; Xu X; Zhang H; Wu S; Zhang J; Zhang T
    Eur J Pharm Sci; 2020 Sep; 152():105463. PubMed ID: 32668314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and Evaluation of 2-Amine-4-oxyphosaniline Pyrimidine Derivatives as EGFR L858R/T790M/C797S Mutant Inhibitors.
    Zhang M; Yang Y; Wang Y; Wang J; Wu H; Zhu Y
    Chem Pharm Bull (Tokyo); 2023 Feb; 71(2):140-147. PubMed ID: 36517026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A sulfonyl fluoride derivative inhibits EGFR
    Ferlenghi F; Scalvini L; Vacondio F; Castelli R; Bozza N; Marseglia G; Rivara S; Lodola A; La Monica S; Minari R; Petronini PG; Alfieri R; Tiseo M; Mor M
    Eur J Med Chem; 2021 Dec; 225():113786. PubMed ID: 34464874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. QSAR of clinically important EGFR mutant L858R/T790M pyridinylimidazole inhibitors.
    Fatima S; Pal D; Agarwal SM
    Chem Biol Drug Des; 2019 Jul; 94(1):1306-1315. PubMed ID: 30811850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.